The partnership's primary goal is to develop a globally standardised IL-2 for solid tumour patients undergoing T-cell therapy. It will focus on localising this standard with affordable pricing for ...

The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate ...

These drugs are designed to deliver a double whammy to tumours, stimulating a local immune response with IL-2 via natural killer cells and cytotoxic T cells, and removing a brake on the immune ...

Stationed within the meninges, squads of immune cells lie in wait, ready to unleash an inflammatory assault within the brain if needed. Holding these trigger-happy troops back during peacetime falls ...

Researchers from Rice University and Baylor College of Medicine have developed a new treatment that eliminates advanced-stage ...

Coya Therapeutics (COYA) announced encouraging blood biomarker data from an investigator-initiated, 21-week, double-blind, placebo-controlled, ...

Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101.

BiTEs as a bridge between the CAR-T cells and other immune cells increase the chances of killing a tumor. Cytokines like interleukin-2 (IL-2) boosts persistence in a CAR-T cell. Oncolytic viruses ...

About Etakafusp Alfa (AB248) Etakafusp alfa (AB248) is a novel CD8+ T cell selective IL-2, generated by fusing a reduced potency IL-2 mutein to an anti-CD8β antibody. It was specifically ...